On friday bby increased the target for acrux to $4.10 from $3.60.They expect sales from axiron to peak at $1.1 billion in fy17.With the approval of ellavie in sweden they say that this should lead to approval in most major european countries within 6 months.They also expect acr to appoint a distribution partner in europe and to earn a royalty of at least 20%.
bby increases acr target to $4.10
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
